Corcym
Corcym is an independent, global medical device company specializing in the development and manufacturing of technologies for cardiac surgery, with a focus on treating structural heart disease. Its portfolio includes both mechanical and biological heart valves and annuloplasty rings utilized for heart valve repair and replacement. The company maintains headquarters in Saluggia, Italy, and operates an additional manufacturing and research facility in Vancouver, Canada.
History
Origins
The origins of Corcym trace back to the Sorin Group, an Italian medical technology firm founded in 1956 by Fiat and Montedison. Initially concentrating on nuclear research, the company later specialized in cardiovascular medical devices. In 2015, Sorin Group merged with the American medical device company Cyberonics, forming LivaNova PLC, consolidating their cardiac surgery and neuromodulation business units.
Formation of Corcym
In December 2020, LivaNova announced plans to divest its heart valve business to the private equity firm Gyrus Capital. [1] The acquisition finalized on 1 April 2021, establishing Corcym as a separate company, incorporating two principal production sites in Saluggia, Italy, and Burnaby (Vancouver), Canada. Approximately 850 employees, as well as the full heart valve product portfolio, were transferred to Corcym.
Operations
Corcym is a privately held entity owned by Gyrus Capital. The company employs approximately 850–900 staff globally and operates in over 100 countries. Its manufacturing and R&D facilities in Saluggia and Vancouver are certified by regulatory agencies including the FDA and the EMA, ensuring compliance for product safety and effectiveness.
Products
Corcym's product offerings encompass mechanical and tissue heart valves, annuloplasty rings, and surgical accessories for treating heart valve disease. Flagship products include the Perceval sutureless aortic valve and the Memo 4D semi-rigid mitral ring, both originally developed during its time under LivaNova. [2] [3] The company is actively advancing clinical studies and invests in innovative minimally invasive surgical solutions.
Corporate structure
- Parent company: Gyrus Capital
- Headquarters: Saluggia, Italy
- Manufacturing and R&D Facilities: Saluggia, Italy, and Vancouver, Canada
- CEO: Christian Mazzi (since 2021)
See also
- Sorin Group
- LivaNova
- Cardiac surgery
References
- ↑ "LivaNova Completes Initial Closing of Heart Valve Business to Gyrus Capital".
- ↑ Deblier, Ivo; De Bock, Dina; Rodrigus, Inez; Mistiaen, Wilhelm (2025-07-28). "The Use of Perceval Valves in Older Patients: A Systematic Review". Reviews in Cardiovascular Medicine. 26 (7). doi:10.31083/RCM39463. ISSN 1530-6550.
- ↑ Dzemali, Omer; Rodriguez Cetina Biefer, Hector; Di Eusanio, Marco; Fabre, Olivier; Troise, Giovanni; Bonaros, Nikolaos; Grimaldi, Francesco; Choi, Yeong-Hoon; Santarpino, Giuseppe; Baeza, Cristian; Pollari, Francesco; Marcheix, Bertrand; Pacini, Davide; Argano, Vincenzo; Baghai, Max (2024-12-25). "Mitral valve repair with the semi-rigid Memo 4D annuloplasty ring: early clinical and echocardiographic outcomes from the MANTRA study". Interdisciplinary CardioVascular and Thoracic Surgery. 40 (1). doi:10.1093/icvts/ivae208. ISSN 2753-670X. PMC 11700519 Check
|pmc=value (help). PMID 39666948 Check|pmid=value (help).
This article "Corcym" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Corcym. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
